Brief: Atara Biotherapeutics Announces Plans To Submit Tab-Cel® BLA In Q2 2024 Following FDA Agreement On Comparability
19/09/2023 22:47
Atara Biotherapeutics Inc ATRA.O :
* ATARA BIOTHERAPEUTICS ANNOUNCES PLANS TO SUBMIT TAB-CEL®
BLA IN
Q2 2024 FOLLOWING FDA AGREEMENT ON COMPARABILITY
* ATARA BIOTHERAPEUTICS INC - EXPECTS TO SUBMIT TAB-CEL BLA
IN Q2
2024
Source text for Eikon: ID:nBw6K1Xy4a
Further company coverage: ATRA.O
Recent news on Atara Biotherapeutics
See all newsBrief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing
Atara Biotherapeutics Q1 revenue drops after prior-year one-time gain
Brief: Atara Biotherapeutics Q1 EPS USD -0.29
NASDAQ RESUMED AT 03:40 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:30 PM